Admission: Verici Dx plc
Verici Dx plc (Verici) has announced its successful raise of £14.5 million (by way of a £12 million placing, £2.1 million subscription and £0.4 million restricted offer) and admission to trading on AIM.
Verici is an immuno-diagnostics development company, initially focussed on the kidney transplantation market. Verici develops tests to understand how a patient is likely and may be responding to kidney transplant. There are two leading products for clinical validation and commercialisation:
- Clarava™, which is a pre-transplant prognosis for the risk of early acute rejection
- Tuteva™, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels.
Crowe's role and team
Crowe acted as reporting accountant to the transaction, with our capital markets team led by Mitesh Patelia, George Lawford and James Leyton.
Client quote
“We valued the assistance of the Capital Markets Team at Crowe in helping us with our successful IPO. They were a pleasure to work with and we appreciated their professional and efficient approach.”
Sara Barrington, Chief Executive Officer, Verici Dx plc
